July 28 (Reuters) - The U.S. Food and Drug

Administration said on Monday it is recommending the removal of

the hold placed on Sarepta Therapeutics' ( SRPT ) gene therapy

Elevidys for patients with a rare muscular disorder who can

walk.

The FDA's recommendation followed a probe that showed

the death of an

8 year old boy

was unrelated to the gene therapy for Duchenne Muscular

Dystrophy, the agency said.